Alpha Profiles · Company Profile

Nuvectis Pharma, Inc.

Canonical company identity and public leadership record.

https://registry.alpha.ac/companies/nuvectis-pharma-inc

Entity: Public listing published
Primary listing: NASDAQ: NVCT
Verification: Partially verified
Last reviewed: 2026-09-22T04:46:32.344222+00:00

Overview

Alpha's canonical identity and public leadership record for Nuvectis Pharma, Inc..

Canonical AEGIS identity graph

Executive leadership

Current, confirmed roles are shown only when both the person Profile and supporting source record satisfy the public projection boundary. A missing role is not evidence that it does not exist.

Executive team

4 public records

Enrique Poradosu

Executive Vice President, Chief Scientific and Business Officer

State: confirmed
Effective: From Feb 11, 2026
Confidence: 94%
Evidence: NVCT 10-K executive officersFeb 11, 2026

Michael Carson

Vice President of Finance

State: confirmed
Effective: From Feb 11, 2026
Confidence: 94%
Evidence: NVCT 10-K executive officersFeb 11, 2026

Ron Bentsur

Chairman, Chief Executive Officer and President

State: confirmed
Effective: From Feb 11, 2026
Confidence: 94%
Evidence: NVCT 10-K executive officersFeb 11, 2026

Shay Shemesh

Executive Vice President, Chief Development and Operations Officer

State: confirmed
Effective: From Feb 11, 2026
Confidence: 94%
Evidence: NVCT 10-K executive officersFeb 11, 2026

Governance leadership

Boards & Committees

Board and committee assignments appear only when the canonical public projection retains a current role and supporting source. Unpublished records are not interpreted as absence.

Record as of Sep 22, 2026. Chair, executive office, Lead Independent Director and committee appointments retain their separate source roles. A complete board composition denominator and committee charters are not established by a partial roster.